Methods for assessing feline immunodeficiency virus infection, infectivity and purification

Veterinary Immunology and Immunopathology

Volumn 143, Issue 3-4, 2011, Pages 202-214

  Ammersbach, Melanie ^a   Bienzle, Dorothee ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Chromatography; Density centrifugation; Lentivirus; Rate zonal centrifugation; Subtilisin digestion; Ultracentrifugation; Viral purification

Indexed keywords

GENOMIC DNA; RNA DIRECTED DNA POLYMERASE; SUBTILISIN; VIRUS RNA;

AFFINITY CHROMATOGRAPHY; ANION EXCHANGE CHROMATOGRAPHY; COPY NUMBER VARIATION; DENSITY GRADIENT CENTRIFUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FELINE IMMUNODEFICIENCY VIRUS; FELINE IMMUNODEFICIENCY VIRUS INFECTION; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; ION EXCHANGE CHROMATOGRAPHY; LENTIVIRUS INFECTION; NONHUMAN; PARTICLE SIZE; PROVIRUS; RATE ZONE CENTRIFUGATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEPARATION TECHNIQUE; SEROLOGY; TANGENTIAL FLOW FILTRATION; TISSUE CULTURE; TRANSMISSION ELECTRON MICROSCOPY; ULTRACENTRIFUGATION; ULTRAFILTRATION; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS PURIFICATION; VIRUS REPLICATION;

ANIMALS; CATS; DNA, VIRAL; ELECTRON MICROSCOPE TOMOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FLOW CYTOMETRY; GENE PRODUCTS, GAG; IMMUNOASSAY; IMMUNODEFICIENCY VIRUS, FELINE; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; SEROLOGIC TESTS;

FELINE IMMUNODEFICIENCY VIRUS; LENTIVIRUS;

EID: 80052347219     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.06.004     Document Type: Review

References (104)

1. Alain R. Quantitation of virus particles by negative stain electron microscopy. Microsc. Today 1997, 97:20.
2. André M., Morgeaux S., Fuchs F. Quantitative detection of RT activity by PERT assay: feasibility and limits to a standardized screening assay for human vaccines. Biologicals 2000, 2:67-80.
3. Andreadis S.T., Roth C.M., Le Doux J.M., Morgan J.R., Yarmush M.L. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol. Prog. 1999, 1:1-11.
4. Bandecchi P., Pistello M., Matteucci D., Lombardi S., Bendinelli M., Tozzini F. Examination of variables affecting syncytium formation by, and serum neutralization of, feline immunodeficiency virus on CrFK cells. New Microbiol. 1995, 3:241-252.
5. Barr M.C., Pough M.B., Jacobson R.H., Scott F.W. Comparison and interpretation of diagnostic tests for feline immunodeficiency virus infection. J. Am. Vet. Med. Assoc. 1991, 10:1377-1381.
6. Bebenek K., Roberts J.D., Kunkel T.A. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem. 1992, 6:3589-3596.
7. Bennett A., Narayan K., Shi D., Hartnell L., Gousset K., He H., Lowekamp B., Yoo T., Bliss D., Freed E., Subramaniam S. Ion-abrasion scanning electron microscopy reveals surface-connected tubular conduits in HIV-infected macrophages. PLoS Pathog. 2009, 5:e1000591.
8. Bess J.W., Gorelick R.J., Bosche W.J., Henderson L.E., Arthur L.O. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 1997, 1:134-144.
9. Bienzle D., Reggeti F., Wen X., Little S., Hobson J., Kruth S. The variability of serological and molecular diagnosis of feline immunodeficiency virus infection. Can. Vet. J. 2004, 9:753-757.
10. Bourinbaiar A.S. The ratio of defective HIV-1 particles to replication-competent infectious virions. Acta Virol. 1994, 1:59-61.
11. Burns J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 1993, 17:8033-8037.
12. Cantin R., Methot S., Tremblay M.J. Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J. Virol. 2005, 11:6577-6587.
13. Chesebro B., Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 1988, 10:3779-3788.
14. Chertova E., Bess J.W., Crise B.J., Sowder I.I.R.C., Schaden T.M., Hilburn J.M., Hoxie J.A., Benveniste R.E., Lifson J.D., Henderson L.E., Arthur L.O. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 2002, 76:5315-5325.
15. Coffi{ligature}n J.M., Hughes S.H., Varmus H.E. Retroviruses 1997, Cold Spring Harbor Laboratory Press, Woodbury, pp. 12-35.
16. Cory J.M., Ohlsson-Wilhelm B.M., Steck M.E., Smithgall M.D., Rozday V., Eyster M.E., Rapp F. Kinetics of infected cell appearance as a determinant of number of human immunodeficiency virus-1 infectious units. AIDS Res. Hum. Retroviruses 1989, 1:97-106.
17. Crawford P.C., Slater M.R., Levy J.K. Accuracy of polymerase chain reaction assays for diagnosis of feline immunodeficiency virus infection in cats. J. Am. Vet. Med. Assoc. 2005, 9:1503-1507.
18. Cruz P.E., Goncalves D., Almeida J., Moreira J.L., Carrondo M.J. Modeling retrovirus production for gene therapy. 2. Integrated optimization of bioreaction and downstream processing. Biotechnol. Prog. 2000, 3:350-357.
19. Darden J.M., Polonis V.R., deSouza M.S., Chantakulkij S., Brown A.E., Birx D.L., Pattanapanyasat K. A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates. Cytometry 2000, 2:141-150.
20. Deneka M., Pelchen-Matthews A., Byland R., Ruiz-Mateos E., Marsh M. In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J. Cell Biol. 2007, 177:329-341.
21. Dettenhofer M., Yu X.F. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J. Virol. 1999, 2:1460-1467.
22. Diehl L.J., Mathiason-Dubard C.K., O'Neil L.L., Hoover E.A. Plasma viral RNA load predicts disease progression in accelerated feline immunodeficiency virus infection. J. Virol. 1996, 4:2503-2507.
23. Eberle J., Seibl R. A new method for measuring reverse transcriptase activity by ELISA. J. Virol. Methods 1992, 3:347-356.
24. Elder J.H., Lin Y.C., Fink E., Grant C.K. Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr. HIV Res. 2010, 1:73-80.
25. Fenyo E.M., Morfeldt-Manson L., Chiodi F., Lind B., von Gegerfelt A., Albert J., Olausson E., Asjo B. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J. Virol. 1988, 11:4414-4419.
26. Fernandez-Garcia A., Cuevas M.T., Munoz-Nieto M., Ocampo A., Pinilla M., Garcia V., Serrano-Bengoechea E., Lezaun M.J., Delgado E., Thomson M., Gonzalez-Galeano M., Contreras G., Najera R., Perez-Alvarez L. Development of a panel of well-characterized human immunodeficiency virus type 1 isolates from newly diagnosed patients including acute and recent infections. AIDS Res. Hum. Retroviruses 2009, 1:93-102.
27. Gao Y., Nankya I., Abraha A., Troyer R.M., Nelson K.N., Rubio A., Arts E.J. Calculating HIV-1 infectious titre using a virtual TCID(50) method. Methods Mol. Biol. 2009, 27-35.
28. Geraerts M., Michiels M., Baekelandt V., Debyser Z., Gijsbers R. Upscaling of lentiviral vector production by tangential flow filtration. J. Gene Med. 2005, 10:1299-1310.
29. Gervaix A., West D., Leoni L.M., Richman D.D., Wong-Staal F., Corbeil J. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc. Natl. Acad. Sci. U.S.A. 1997, 9:4653-4658.
30. Gluschankof P., Mondor I., Gelderblom H.R., Sattentau Q.J. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology 1997, 1:125-133.
31. Goff S., Traktman P., Baltimore D. Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J. Virol. 1981, 1:239-248.
32. Gorbunoff M.J. The interaction of proteins with hydroxyapatite: I. Role of protein charge and structure. Anal. Biochem. 1984, 2:425-432.
33. Gorbunoff M.J. The interaction of proteins with hydroxyapatite: II. Role of acidic and basic groups. Anal. Biochem. 1984, 2:433-439.
34. Goto Y., Nishimura Y., Baba K., Mizuno T., Endo Y., Masuda K., Ohno K., Tsujimoto H. Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virus. J. Virol. 2002, 19:10079-10083.
35. Gould S.J., Booth A.M., Hildreth J.E. The Trojan exosome hypothesis. Proc. Natl. Acad. Sci. U.S.A. 2003, 19:10592-10597.
36. Hahon N., Simpson J., Eckert H.L. Assessment of virus infectivity by the immunofluorescent and immunoperoxidase techniques. J. Clin. Microbiol. 1975, 3:324-329.
37. Heneine W., Yamamoto S., Switzer W.M., Spira T.J., Folks T.M. Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 1995, 5:1210-1216.
38. Hokanson R.M., TerWee J., Choi I.S., Coates J., Dean H., Reddy D.N., Wolf A.M., Collisson E.W. Dose response studies of acute feline immunodeficiency virus PPR strain infection in cats. Vet. Microbiol. 2000, 4:311-327.
39. Inoshima Y., Tomonaga K., Ikeda Y., Miyazawa T., Mikami T. Quantification of feline immunodeficiency virus (FIV) proviral DNA in peripheral blood mononuclear cells of cats infected with Japanese strains of FIV. J. Vet. Med. Sci. 1995, 3:487-492.
40. Ishida T., Washizu T., Toriyabe K., Motoyoshi S., Tomoda I., Pedersen N.C. Feline immunodeficiency virus infection in cats of Japan. J. Am. Vet. Med. Assoc. 1989, 2:221-225.
41. Kesimer M., Scull M., Brighton B., DeMaria G., Burns K., O'Neal W., Pickles R.J., Sheehan J.K. Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J. 2009, 6:1858-1868.
42. Kimpton J., Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 1992, 4:2232-2239.
43. Koot M., Vos A.H., Keet R.P., de Goede R.E., Dercksen M.W., Terpstra F.G., Coutinho R.A., Miedema F., Tersmette M. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992, 1:49-54.
44. Kuiper M., Sanches R.M., Walford J.A., Slater N.K. Purification of a functional gene therapy vector derived from Moloney murine leukaemia virus using membrane filtration and ceramic hydroxyapatite chromatography. Biotechnol. Bioeng. 2002, 4:445-453.
45. Kutner R.H., Puthli S., Marino M.P., Reiser J. Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol. 2009, 9:10.
46. Kutner R.H., Zhang X.Y., Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc. 2009, 4:495-505.
47. Kwon Y.J., Hung G., Anderson W.F., Peng C.A., Yu H. Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis. J. Virol. 2003, 10:5712-5720.
48. Layne S.P., Merges M.J., Dembo M., Spouge J.L., Conley S.R., Moore J.P., Raina J.L., Renz H., Gelderblom H.R., Narat P.L. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992, 2:695-714.
49. Lee M.H., Sano K., Morales F.E., Imagawa D.T. Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus. J. Clin. Microbiol. 1987, 9:1717-1721.
50. Levy J.K., Crawford P.C., Slater M.R. Effect of vaccination against feline immunodeficiency virus on results of serologic testing in cats. J. Am. Vet. Med. Assoc. 2004, 10:1558-1561.
51. Lorentzen L., Caola A.E. Incidence of positive heartworm antibody and antigen tests at IDEXX Laboratories: trends and potential impact on feline heartworm awareness and prevention. Vet. Parasitol. 2008, 3:183-190.
52. Luttge B.G., Freed E.O. FIV Gag: virus assembly and host-cell interactions. Vet. Immunol. Immunopathol 2010, 1-2:3-13.
53. Makino M., Ishikawa G., Yamaguchi K., Okada Y., Watanabe K., Sasaki-Iwaki Y., Manabe S., Honda M., Komuro K. Concentration of live retrovirus with a regenerated cellulose hollow fiber. BMM. Arch. Virol. 1994, 1-2:87-96.
54. Marcom K.A., Brodie S.J., Pearson L.D., DeMartini J.C. Analysis of ovine lentivirus infectivity and replication by using a focal immunoassay and an antigen-capture enzyme-linked immunosorbent assay. J. Clin. Microbiol. 1992, 11:2852-2858.
55. Marozsan A.J., Fraundorf E., Abraha A., Baird H., Moore D., Troyer R., Nankja I., Arts E.J. Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J. Virol. 2004, 20:11130-11141.
56. Martinez M.A., Vartanian J.P., Wain-Hobson S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl. Acad. Sci. U.S.A. 1994, 25:11787-11791.
57. Mascola J.R., Louder M.K., Winter C., Prabhakara R., De Rosa S.C., Douek D.C., Hill B.J., Gabuzda D., Roederer M. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 2002, 10:4810-4821.
58. McGrath M., Witte O., Pincus T., Weissman I.L. Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity. J. Virol. 1978, 3:923-927.
59. Miyazawa T., Tomonaga K., Kawaguchi Y., Mikami T. The genome of feline immunodeficiency virus. Arch. Virol. 1994, 3-4:221-234.
60. Møller-Larsen A., Christensen T. Isolation of a retrovirus from multiple sclerosis patients in self-generated Iodixanol gradients. J. Virol. Methods 1998, 2:151-161.
61. Nguyen D.G., Booth A., Gould S.J., Hildreth J.E. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J. Biol. Chem. 2003, 52:52347-52354.
62. O'Connor T.P., Tanguay S., Steinman R., Smith R., Barr M.C., Yamamoto J.K., Pedersen N.C., Andersen P.R., Tonelli Q.J. Development and evaluation of immunoassay for detection of antibodies to the feline T-lymphotropic lentivirus (feline immunodeficiency virus). J. Clin. Microbiol. 1989, 3:474-479.
63. Ott D.E. Purification of HIV-1 virions by subtilisin digestion or CD45 immunoaffinity depletion for biochemical studies. Methods Mol. Biol. 2009, 15-25.
64. Ott D.E. Cellular proteins detected in HIV-1. Rev. Med. Virol. 2008, 3:159-175.
65. Ott D.E., Coren L.V., Johnson D.G., Kane B.P., Sowder R.C., Kim Y.D., Fisher R.J., Zhou X.Z., Lu K.P., Henderson L.E. Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology 2000, 1:42-51.
66. Ott D.E., Coren L.V., Kane B.P., Busch L.K., Johnson D.G., Sowder R.C., Chertova E.N., Arthur L.O., Henderson L.E. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J. Virol. 1996, 11:7734-7743.
67. Overbaugh J., Luciw P.A., Hoover E.A. Models for AIDS pathogenesis: simian immunodeficiency virus, simian-human immunodeficiency virus and feline immunodeficiency virus infections. AIDS, Supplement A 1997, S47-54.
68. Paul R.W., Morris D., Hess B.W., Dunn J., Overell R.W. Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum. Gene Ther. 1993, 5:609-615.
69. Pedersen N.C., Ho E.W., Brown M.L., Yamamoto J.K. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987, 4790:790-793.
70. Pinches M.D., Diesel G., Helps C.R., Tasker S., Egan K., Gruffydd-Jones T.J. An update on FIV and FeLV test performance using a Bayesian statistical approach. Vet. Clin. Pathol. 2007, 2:141-147.
71. Pincus S.H., Wehrly K., Chesebro B. Use of a focal infectivity assay for testing susceptibility of HIV to antiviral agents. BioTechniques 1991, 3:336-342.
72. Platt E.J., Kozak S.L., Durnin J.P., Hope T.J., Kabat D. Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J. Virol. 2010, 6:3106-3110.
73. Preston B.D., Poiesz B.J., Loeb L.A. Fidelity of HIV-1 reverse transcriptase. Science 1988, 4882:1168-1171.
74. Pyra H., Boni J., Schupbach J. Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. Proc. Natl. Acad. Sci. U.S.A. 1994, 4:1544-1548.
75. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
76. Remington K.M., Chesebro B., Wehrly K., Pedersen N.C., North T.W. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J. Virol. 1991, 1:308-312.
77. Sastry L., Xu Y., Duffy L., Koop S., Jasti A., Roehl H., Jolly D., Cornetta K. Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection. Hum. Gene Ther. 2005, 10:1227-1236.
78. Scherr M., Battmer K., Eder M., Schule S., Hohenberg H., Ganser A., Grez M., Blomer U. Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther. 2002, 24:1708-1714.
79. Schneider J., Kaaden O., Copeland T.D., Oroszlan S., Hunsmann G. Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J. Gen. Virol. 1986, 67:2533-2538.
80. Sears J.F., Repaske R., Khan A.S. Improved Mg2+-based reverse transcriptase assay for detection of primate retroviruses. J. Clin. Microbiol. 1999, 6:1704-1708.
81. Segura M.M., Garnier A., Durocher Y., Ansorge S., Kamen A. New protocol for lentiviral vector mass production. Methods Mol. Biol. 2010, 39-52.
82. Segura M.M., Garnier A., Durocher Y., Coelho H., Kamen A. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol. Bioeng. 2007, 4:789-799.
83. Segura M.M., Kamen A., Trudel P., Garnier A. A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol. Bioeng. 2005, 4:391-404.
84. Segura M.d.l.M., Garnier A., Kamen A. Purification and characterization of retrovirus vector particles by rate zonal ultracentrifugation. J. Virol. Methods 2006, 1:82-91.
85. Silver J., Maudru T., Fujita K., Repaske R. An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions. Nucleic Acids Res. 1993, 15:3593-3594.
86. Smith J.M., Dauner A., Li B., Srinivasan P., Mitchell J., Hendry M., Ellenberger D., Butera S., Otten R.A. Generation of a dual RT Env SHIV that is infectious in rhesus macaques. J. Med. Primatol. 2010, 4:213-223.
87. Speelmon E.C., Livingston-Rosanoff D., Desbien A.L., Lee J., Wick W.D., Hladik F., McElrath M.J. Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals. AIDS Res. Hum. Retroviruses 2008, 11:1415-1427.
88. Tilton G.K., O'Connor T.P., Seymour C.L., Lawrence K.L., Cohen N.D., Andersen P.R., Tonelli Q.J. Immunoassay for detection of feline immunodeficiency virus core antigen. J. Clin. Microbiol. 1990, 5:898-904.
89. Tjøtta E., Hungnes O., Grinde B. An assay for quantifying infectious HIV particles. J. Virol. Methods 1990, 2:169-174.
90. Tozzini F., Matteucci D., Bandecchi P., Baldinotti F., Poli A., Pistello M., Siebelink K.H.J., Ceccherini-Nelli L., Bendinelli M. Simple in vitro methods for titrating Feline Immunodeficiency Virus (FIV) and FIV neutralizing antibodies. J. Virol. Methods 1992, 3:241-252.
91. Transfiguracion J., Coelho H., Kamen A. High-performance liquid chromatographic total particles quantification of retroviral vectors pseudotyped with vesicular stomatitis virus-G glycoprotein. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2004, 1-2:167-173.
92. Trubey C.M., Chertova E., Coren L.V., Hilburn J.M., Hixson C.V., Nagashima K., Lifson J.D., Ott D.E. Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles. J. Virol. 2003, 23:12699-12709.
93. Tsai W.P., Conley S.R., Kung H.F., Garrity R.R., Nara P.L. Preliminary in vitro growth cycle and transmission studies of HIV-1 in an autologous primary cell assay of blood-derived macrophages and peripheral blood mononuclear cells. Virology 1996, 2:205-216.
94. Urabe T., Sano K., Tanno M., Mizoguchi J., Otani M., Lee M.H., Takasaki T., Kusakabe H., Imagawa D.T., Nakai M. A non-radioisotopic reverse transcriptase assay using biotin-11-deoxyuridinetriphosphate on primer-immobilized microtiter plates. J. Virol. Methods 1992, 2:145-154.
95. Vahlenkamp T.W., Egberink H.F., van Eijk M.J.T., Slotboom-Kamphorst A.M.E., Verschoor E.J., Horzinek M.C., de Ronde A. Competitive reverse transcription-polymerase chain reaction for quantitation of feline immunodeficiency virus. J. Virol. Methods 1995, 3:335-346.
96. Vartanian J.P., Meyerhans A., Sala M., Wain-Hobson S. G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. U.S.A. 1994, 8:3092-3096.
97. Wagaman P.C., Hasselkus-Light C.S., Henson M., Lerner D.L., Phillips T.R., Elder J.H. Molecular cloning and characterization of deoxyuridine triphosphatase from feline immunodeficiency virus (FIV). Virology 1993, 2:451-457.
98. Welsch S., Keppler O.T., Habermann A., Allespach I., Kriinse-Lcoker J., Kräusslich H.G. HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog. 2007, 3:e36.
99. Williams S.L., Eccleston M.E., Slater N.K. Affinity capture of a biotinylated retrovirus on macroporous monolithic adsorbents: towards a rapid single-step purification process. Biotechnol. Bioeng. 2005, 7:783-787.
100. Williams S.L., Nesbeth D., Darling D.C., Farzaneh F., Slater N.K. Affinity recovery of Moloney Murine Leukaemia Virus. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2005, 1:111-119.
101. Yamada K., McCarty D.M., Madden V.J., Walsh C.E. Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. BioTechniques 2003, 5. pp. 1074-1078, 1080.
102. Yamamoto J.K., Sanou M.P., Abbott J.R., Coleman J.K. Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr. HIV Res. 2010, 1:14-25.
103. Ye K., Jin S., Ataai M.M., Schultz J.S., Ibeh J. Tagging retrovirus vectors with a metal binding peptide and one-step purification by immobilized metal affinity chromatography. J. Virol. 2004, 18:9820-9827.
104. Zhang R., Nguyen T.T. Model of human immunodeficiency virus budding and self-assembly: role of the cell membrane. Phys. Rev. E: Stat. Nonlin. Soft Matter Phys. 2008, 5(Pt 1):051903.